

Asymptomatic SARS-CoV-2 infection: the tip or the iceberg?

Alexander J Keeley,^{1,2,3} Cariad M Evans,^{2,3} Thushan I de Silva^{1,2}

Cruise ships, with their unique enclosed environment, have provided valuable insights into the dynamics of viral transmission during the COVID-19 pandemic. On the Diamond Princess cruise ship in Yokohama, Japan, approximately 21% of those on board tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with 51.7% of these representing asymptomatic infections at the time of testing.¹ In this month's edition of *Thorax*, Ing *et al* describe an outbreak on a cruise ship departing Argentina for the Antarctic peninsula with 223 members, all of whom were screened with temperature and symptom check prior to embarkation in mid-March 2020. At day 8, the first member developed symptoms. Despite immediate imposition of cabin isolation of all passengers and strict personal protective equipment use by crew, 128 (59.0%) of those on board tested positive for SARS-CoV-2 on day 20, when everyone was screened with an RT-PCR-based test. Of those testing positive, only 24 (18.8%) developed symptoms and 104 (81.2%) remained asymptomatic until day 28, when the first cohort of passengers disembarked. Some caution is required in interpreting this figure as the follow-up period is not long enough to be confident that all individuals remained truly asymptomatic. Nevertheless, it is striking that despite rigorous attempts to limit spread, such widespread transmission occurred on board. The enclosed environment may be the major driver of the high transmission rate; however, the possibility that transmission from asymptomatic cases contributed significantly must also be considered.

Asymptomatic infection is often understood as detection of SARS-CoV-2 by RT-PCR, in the absence of a clinical illness compatible with COVID-19. In practice, reported asymptomatic infections encompass a heterogeneous mixture

of paucisymptomatic infection (where symptoms are present but are mild or non-specific), presymptomatic infection (where RT-PCR is positive and symptoms emerge shortly afterwards), missed infection (where RT-PCR is positive in a person who retrospectively reports symptoms) and true asymptomatic infection (those actively monitored for 14 days for symptom development). Regardless of how these cases are categorised, any case where there is an infection without recognition, and therefore without behaviour change, risks onward transmission.

Understanding the nature and role of asymptomatic SARS-CoV-2 infection is crucial to inform public health strategies to tackle COVID-19. Three key steps are required: the proportion of asymptomatic SARS-CoV-2 infection must be characterised, the role of asymptomatic infection in onward transmission in different settings must be established, and interventions to recognise and limit the spread from asymptomatic cases must be evaluated.

It is increasingly clear that the context of the investigation likely accounts for the wide-ranging estimates of asymptomatic infection prevalence and proportion reported to date. A systematic review, currently in preprint, identified five studies with a clearly defined sampling frame and adequate follow-up to distinguish true asymptomatic from presymptomatic infection. The pooled proportion of asymptomatic infection was 16% (95% CI 12% to 20%).² Community RT-PCR testing of the entire village of Vo in Italy, at two time points, demonstrated an overall infection prevalence of 2.6% at the start of lockdown and 1.2% at the end of lockdown, with 43% of all infections being asymptomatic.³ Data from screening healthcare workers (HCWs), where unrecognised infection may have significant consequences for nosocomial transmission, suggest a low overall prevalence of asymptomatic infection. Asymptomatic HCW screening in a London hospital showed a prevalence of 7% in late March, reducing to 1% in late April.⁴ In Cambridge, UK, screening of 1032 HCW in April revealed 30 (3%) positive cases, of whom only 5 were considered truly asymptomatic.⁵ Perhaps more comparable to the contained environment of cruise ships are data from residential home outbreaks,

revealing a high prevalence of infection. In a residential home in Washington, USA, with 89 residents, 55 (62%) tested positive over 3 weeks.⁶ Although 27 (49%) were asymptomatic at the time of testing, only 3 (5%) remained asymptomatic throughout the observed follow-up period of at least 7 days. Furthermore, during follow up of 96 asymptomatic cases from the Diamond Princess cruise ship, 11 individuals subsequently developed symptoms, with a greater risk of illness in older patients.⁷

Onward transmission from asymptomatic infection was first described in China, where an index case transmitted infection to all five members of a family despite remaining asymptomatic throughout.⁸ Investigation of 30 patients in Vietnam revealed lower viral loads in those who were asymptomatic, with epidemiological investigation revealing at least 3 cases which had been acquired through contact with asymptomatic sources.⁹ In Guangzhou, China, 4950 contacts of 129 confirmed cases, including 8 asymptomatic cases, were serially screened with RT-PCR every 2 days.¹⁰ A single infection (0.3%) occurred in 305 contacts of the asymptomatic cases compared with 116 infections (5%) in 2305 contacts of symptomatic cases.

The cruise ship outbreak described by Ing *et al* raises another interesting question relating to the variability in risk of onward transmission from infected cases (the overdispersion parameter), where sometimes a high number of secondary cases arise from a presumed single source.¹¹ Mathematical modelling has estimated that 80% of secondary transmissions may occur from as few as 10% of cases.¹² If asymptomatic cases are demonstrated to contribute to these so-called 'superspreading' events, then any intervention in the assessment of an outbreak must be able to recognise and manage such cases.

The wider implications of screening for asymptomatic infection as part of effective interventions to reduce transmission of SARS-CoV-2 are particularly relevant as governments implement strategies to release lockdown measures. The current mainstay of intervention relies on identification of infection, case isolation, implementation of infection control measures and contact tracing. Mass indiscriminate RT-PCR testing of asymptomatic groups requires careful consideration of laboratory testing capacity and interpretation of test results in the context of non-infectious, prolonged RT-PCR positivity in convalescence.¹³ However, in outbreak scenarios,

¹South Yorkshire Regional Department of Infection and Tropical Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

²Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK

³Department of Virology, Laboratory Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

Correspondence to Dr Thushan I de Silva, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield S10 2RX, UK; t.desilva@sheffield.ac.uk

where a high prevalence of asymptomatic infection from point prevalence data has been repeatedly demonstrated, mass screening represents a valuable tool to identify asymptomatic (including paucisymptomatic, and presymptomatic) cases, that would otherwise go unrecognised. This could be employed in care homes, in cruise ships, in hospital outbreaks or other community clusters, in order to promptly and completely interrupt chains of transmission. Determining whether transmission from asymptomatic cases is a rare event or a significant driver of SARS-CoV-2 spread must be a research priority, allowing both cruise ships and governments to safely navigate a path out of this pandemic.

Twitter Alexander J Keeley @AlexJKeeley, Cariad M Evans @cariadmevans and Thushan I de Silva @Thushan_deSilva

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Commissioned; externally peer reviewed.

Data availability statement No data are available.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until

otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Keeley AJ, Evans CM, de Silva TI. *Thorax* 2020;**75**:621–622.

Received 4 June 2020

Accepted 6 June 2020

Published Online First 24 June 2020



► <http://dx.doi.org/10.1136/thoraxjnl-2020-215091>

Thorax 2020;**75**:621–622.

doi:10.1136/thoraxjnl-2020-215337

REFERENCES

- 1 Mizumoto K, Kagaya K, Zarebski A, *et al.* Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the diamond Princess cruise SHIP, Yokohama, Japan, 2020. *Eurosurveillance* 2020;**25**:2000180.
- 2 Byambasuren O, Cardona M, Bell K, *et al.* Estimating the extent of true asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. *medRxiv* 2020.
- 3 Lavezzo E, Franchin E, Ciavarella C, *et al.* Suppression of COVID-19 outbreak in the municipality of Vo, Italy. *medRxiv* 2020.

- 4 Treibel TA, Manisty C, Burton M, *et al.* COVID-19: PCR screening of asymptomatic health-care workers at London Hospital. *Lancet* 2020;**395**:1608–10.
- 5 Rivett L, Sridhar S, Sparkes D, *et al.* Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. *Elife* 2020;**9**:e58728.
- 6 Arons MM, Hatfield KM, Reddy SC, *et al.* Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. *N Engl J Med* 2020;**382**:2081–90.
- 7 Sakurai A, Sasaki T, Kato S, *et al.* Natural history of asymptomatic SARS-CoV-2 infection. *N Engl J Med* 2020. doi:10.1056/NEJMc2013020. [Epub ahead of print: 12 Jun 2020].
- 8 Bai Y, Yao L, Wei T, *et al.* Presumed asymptomatic carrier transmission of COVID-19. *JAMA* 2020. doi:10.1001/jama.2020.2565. [Epub ahead of print: 21 Feb 2020].
- 9 Chau NVV, Thanh Lam V, Thanh Dung N, *et al.* The natural history and transmission potential of asymptomatic SARS-CoV-2 infection. *Clin Infect Dis* 2020. doi:10.1093/cid/ciaa711. [Epub ahead of print: 04 Jun 2020].
- 10 Lei Luo DL, Liao X-long, Wu X-bo, *et al.* Modes of contact and risk of transmission in COVID-19 among close contacts. *medRxiv* 2020.
- 11 Hamner L, Dubbel P, Capron I, *et al.* High SARS-CoV-2 attack rate following exposure at a Choir practice - Skagit County, Washington, March 2020. *MMWR Morb Mortal Wkly Rep* 2020;**69**:606–10.
- 12 Endo A, Abbott S, Kucharski AJ, *et al.* Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China. *Wellcome Open Res* 2020;**5**:67.
- 13 Wajnberg A, Mansour M, Leven E, *et al.* Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region. *medRxiv* 2020.